Andy Sassine is the Chief Financial Officer and a Director at Arcturus Therapeutics Holdings Inc., a leading biotechnology company focused on developing innovative RNA-based therapeutics. With an extensive background in finance and strategic management, Sassine brings a wealth of experience to his role. He has been instrumental in guiding Arcturus through its growth phases, overseeing financial strategies that have supported the company's research and development initiatives. Prior to joining Arcturus, Sassine held several high-profile positions in the finance sector. He served as the Managing Director at Cantor Fitzgerald Canada Corporation, where he was responsible for leading the firm's investment banking efforts in the life sciences sector. His expertise in capital markets and corporate finance has been pivotal in his ability to drive Arcturus' financial strategy. Sassine's achievements include successfully raising capital for the company and establishing key partnerships that have bolstered Arcturus' position in the competitive biotech industry. In his current role at Arcturus, Sassine is responsible for the overall financial health of the company, including budgeting, financial planning, and investor relations. His strategic vision has been crucial in navigating the complex landscape of biotechnology finance, ensuring that Arcturus remains well-funded and positioned for future growth. Sassine's leadership and financial acumen continue to play a vital role in advancing Arcturus' mission to develop transformative RNA medicines.